Curis (NASDAQ:CRIS) Releases Quarterly Earnings Results

Curis (NASDAQ:CRIS) issued its quarterly earnings results on Thursday. The biotechnology company reported ($1.94) EPS for the quarter, beating analysts’ consensus estimates of ($2.01) by $0.07, Zacks reports.

Curis Stock Performance

Shares of NASDAQ CRIS traded down $0.02 during mid-day trading on Thursday, reaching $0.57. The company had a trading volume of 424,225 shares, compared to its average volume of 1,241,869. Curis has a one year low of $0.33 and a one year high of $28.40. The firm has a market cap of $2.35 million, a price-to-earnings ratio of -0.04 and a beta of 3.28. The business’s 50-day simple moving average is $0.80 and its 200 day simple moving average is $8.39.

Analyst Ratings Changes

CRIS has been the topic of several analyst reports. HC Wainwright reissued a “buy” rating on shares of Curis in a research report on Monday, August 17th. Weiss Ratings restated a “sell (e+)” rating on shares of Curis in a research note on Thursday, October 15th. Zacks Research upgraded Curis from a “strong sell” rating to a “hold” rating in a report on Wednesday, September 9th. Finally, Wall Street Zen raised Curis from a “strong sell” rating to a “hold” rating in a research report on Saturday, August 22nd. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $43.00.

About Curis

Curis, Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutics for the treatment of cancer. The company’s research and development activities center on targeted therapies designed to address biological pathways involved in tumor growth and immune regulation. Curis’ lead investigational product is emavusertib, an oral inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4). The company has evaluated emavusertib in clinical studies for hematologic malignancies, including acute myeloid leukemia, myelodysplastic syndromes and certain forms of non-Hodgkin lymphoma.